Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
2017년 12월 4일 업데이트: GlaxoSmithKline
A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination With Docetaxel (Taxotere)
This is a safety and tolerability study of GW572016 given with docetaxel (TAXOTERE).
연구 개요
연구 유형
중재적
등록 (실제)
52
단계
- 1단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
Michigan
-
Detroit, Michigan, 미국, 48201
- GSK Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- GSK Investigational Site
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- Advanced solid tumors.
- Able to swallow oral medication.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: All treated subjects
All subjects received Lapatinib in Combination with Docetaxel (Taxotere)
|
도세탁셀
lapatinib
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of subjects with adverse events (AEs) or serious AEs (SAEs)
기간: Up to 7 weeks in each cycle
|
An AE is any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require medical or surgical intervention will be categorized as SAE.
|
Up to 7 weeks in each cycle
|
|
Number of subjects with abnormal change from Baseline in laboratory parameters
기간: Baseline and up to 7 weeks in each cycle
|
Blood sample will be collected to evaluate laboratory parameters.
|
Baseline and up to 7 weeks in each cycle
|
|
Number of subjects with Optimally Tolerated regimen
기간: Up to 7 weeks in each cycle
|
Optimally Tolerated regimen is a dose regimen where 1 out of 6 subjects experiences a dose-limiting toxicity (DLT).
|
Up to 7 weeks in each cycle
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Area under the plasma drug concentration curve (AUC) from 0 to infinity (AUC[0-inf]) of docetaxel alone (Pharmacokinetic [PK] cohort 1)
기간: Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.
|
|
AUC within the dosing interval (AUC[0-tau]) of GW572016 alone (PK cohort 2)
기간: Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.
|
|
AUC (0-tau) of GW572016 when given in combination with docetaxel (PK cohort 1)
기간: Sequence 1, Day 22 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 22 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion.
|
|
AUC (0-tau) of GW572016 when given in combination with docetaxel (PK cohort 2)
기간: Sequence 1, Day 23 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 23 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion
|
|
Maximum observed plasma drug concentration (Cmax) of docetaxel alone (PK cohort 1)
기간: Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.
|
|
Cmax of GW572016 alone (PK cohort 2)
기간: Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.
|
|
Cmax of GW572016 when given in combination with docetaxel (PK cohort 1)
기간: Sequence 1, Day 22 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 22 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion.
|
|
Cmax of GW572016 when given in combination with docetaxel (PK cohort 2)
기간: Sequence 1, Day 23 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 23 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion
|
|
Time to maximum observed plasma drug concentration (Tmax) of docetaxel alone (PK cohort 1)
기간: Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.
|
|
Tmax of GW572016 alone (PK cohort 2)
기간: Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.
|
|
Tmax of GW572016 when given in combination with docetaxel (PK cohort 1)
기간: Sequence 1, Day 22 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 22 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion.
|
|
Tmax of GW572016 when given in combination with docetaxel (PK cohort 2)
기간: Sequence 1, Day 23 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 23 and Sequence 2, Day 1: Prior to the GW572016 oral dose and docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the start of the docetaxel infusion
|
|
Concentration at the last measurable time point (Ctau) for GW572016 along (PK cohort 2)
기간: Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.
|
|
Time to first measurable plasma drug concentration (Tlag) for GW572016 along (PK cohort 2)
기간: Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 1 and Sequence 2, Day 21: Prior to GW572016 dose and at 20 and 40 minutes; 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after the dose.
|
|
AUC from time zero to time of last measurable concentration (AUClast) for docetaxel alone (PK cohort 1)
기간: Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.
|
|
Clearance (CL) for docetaxel alone (PK cohort 1)
기간: Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.
|
|
Volume of distribution at steady state (Vss) for docetaxel alone (PK cohort 1)
기간: Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.
|
|
Elimination half-life (Thalf) for docetaxel alone (PK cohort 1)
기간: Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.
|
Blood samples will be collected at indicated time points to evaluate pharmacokinetic parameters.
|
Sequence 1, Day 1 and Sequence 2, Day 22: Prior to the docetaxel infusion, at 20 and 40 minutes after the start of the infusion, at 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours after start of the infusion.
|
|
Number of subjects with complete response
기간: Week 3 of every third cycle
|
Efficacy assessments will be obtained every three cycles depending on standard practices in specific tumor type.
|
Week 3 of every third cycle
|
|
Number of subjects with partial response
기간: Week 3 of every third cycle
|
Efficacy assessments will be obtained every three cycles depending on standard practices in specific tumor type.
|
Week 3 of every third cycle
|
|
Number of subjects with stable disease
기간: Week 3 of every third cycle
|
Efficacy assessments will be obtained every three cycles depending on standard practices in specific tumor type.
|
Week 3 of every third cycle
|
|
Number of subjects with progressive disease
기간: Week 3 of every third cycle
|
Efficacy assessments will be obtained every three cycles depending on standard practices in specific tumor type.
|
Week 3 of every third cycle
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2003년 4월 28일
기본 완료 (실제)
2006년 1월 21일
연구 완료 (실제)
2006년 1월 21일
연구 등록 날짜
최초 제출
2005년 9월 6일
QC 기준을 충족하는 최초 제출
2005년 9월 6일
처음 게시됨 (추정)
2005년 9월 8일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2017년 12월 6일
QC 기준을 충족하는 마지막 업데이트 제출
2017년 12월 4일
마지막으로 확인됨
2017년 12월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
신생물, 유방에 대한 임상 시험
도세탁셀에 대한 임상 시험
-
Hebei Medical University Fourth Hospital완전한